drugset / Trial / NCT00774020

Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)

NCT00774020

Phase 4 Completed 9 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to document the efficacy and safety profiles of single intravenous dose of 5 mg zoledronic acid for the Chinese patients of Paget's Disease of Bone (PDB).

Timeline

Start
2008-10-30
Primary completion
2011-01-14
Completion
2011-01-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified 5 mg Intravenous

Indications